
US drugmaker Eli Lilly (NYSE: LLY) has pulled out of the partnership with Transition Therapeutics (TSX: TTH) to develop its …
Transition Therapeutics is to abandon trials of its new diabetes treatment TT-223 following disappointing trial results. The Canadian biopharma company …

The Niagara Falls are one of the wonders of the natural world, and every year millions of visitors from around …
Migraine annual economic and quality-of-life burden in UK
bit.bio expands human heart cell portfolio through myriamed partnership
Phoenix Labs acquires Kent Pharma
Astoriom acquires Sampled’s UK stability storage operations
Alcami appoints Will Isom to lead laboratory services sales

